Pegex is a prescription medication that contains 6mg of Pegfilgrastim, a granulocyte-colony stimulating factor (G-CSF) used to help reduce the risk of neutropenia (low white blood cell count) in patients with cancer. It is available in injectable form.
Composition:
Pegex contains 6mg of Pegfilgrastim, a white or off-white powder.
Mechanism of Action:
Pegfilgrastim works by:
- Stimulating the production of white blood cells, specifically neutrophils, in the bone marrow
- Increasing the number of neutrophils in the blood
- Reducing the risk of neutropenia and related complications
Indication:
Pegex is indicated for:
- Reducing the risk of neutropenia in patients with cancer receiving myelosuppressive chemotherapy
- Reducing the risk of febrile neutropenia (infection accompanied by a low white blood cell count) in patients with cancer receiving myelosuppressive chemotherapy
Dosage:
The recommended dosage of Pegex is:
- 6mg administered subcutaneously (under the skin) 24 hours after the start of chemotherapy and again 7 days after the first dose
Side Effects:
Common side effects of Pegex may include:
- Pain, redness, or swelling at the injection site
- Mild to moderate bone pain
- Fatigue
- Headache
- Dizziness
- Increased risk of bone marrow suppression (reduced blood cell count)
Recommendation:
Pegex should only be used under the guidance of a healthcare provider. Patients receiving Pegex treatment should be closely monitored for side effects and potential complications.
Important Note:
- Pegex is not intended to treat or prevent infections. Patients receiving Pegex should continue to receive appropriate antibiotic treatment for infections.
- Patients with a history of severe allergic reactions to pegfilgrastim or other G-CSF medications should not receive Pegex.
- Patients with a history of severe bone marrow suppression or other bone marrow disorders should be closely monitored while receiving Pegex.
Special Precautions:
- Patients with a history of severe kidney disease or severe liver disease should be closely monitored while receiving Pegex.
- Patients with a history of severe cardiac disease or hypertension should be closely monitored while receiving Pegex.
It is important to note that the dosage and administration of Pegex may vary depending on the patient’s individual needs and medical history. It is recommended that patients consult their healthcare provider before taking this medication.
Reviews
There are no reviews yet.